Sachin Mehta, MD
Psychiatry · Blue Bell, PANPI 1295926194
Payments from drug & device makers
Across 1,259 payments — averaging $513.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$176K
- E.r. Squibb & Sons, L.L.C.$135K
- AbbVie$121K
- Alkermes, Inc.$70K
- Axsome Therapeutics, Inc.$65K
- Teva Pharmaceuticals USA, Inc.$38K
- plus $40K from 23 others
What the payments were for
- Consulting fees$39,4516%
- Speaking & faculty fees$517,47980%
- Travel & lodging$58,7109%
- Food & beverage$30,1005%
- Education$1880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 253 | $176,187 |
| E.r. Squibb & Sons, L.L.C. | 120 | $135,411 |
| AbbVie(2 entities) | 262 | $121,440 |
| Alkermes, Inc. | 150 | $70,462 |
| Axsome Therapeutics, Inc. | 77 | $64,564 |
| Teva Pharmaceuticals USA, Inc. | 46 | $37,770 |
| Idorsia Pharmaceuticals US Inc | 33 | $24,382 |
| Corium, LLC | 43 | $8,701 |
| Biogen | 2 | $1,569 |
| Otsuka America Pharmaceutical, Inc. | 52 | $1,089 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $796 |
| Johnson & Johnson | 22 | $568 |
| Lundbeck LLC | 25 | $429 |
| Neurocrine Biosciences, Inc. | 17 | $376 |
| Vanda Pharmaceuticals Inc. | 16 | $369 |
| Ironshore Pharmaceuticals Inc. | 16 | $352 |
| Supernus Pharmaceuticals, Inc. | 13 | $350 |
| Sunovion Pharmaceuticals Inc. | 26 | $347 |
| Neos Therapeutics, LP | 8 | $173 |
| Bausch Health US, LLC | 6 | $127 |
| Tris Pharma Inc | 6 | $107 |
| Collegium Pharmaceutical, Inc. | 4 | $86 |
| Almatica Pharma LLC | 3 | $65 |
| Indivior Inc. | 2 | $60 |
| Novartis | 1 | $50 |
| Neuronetics, Inc. | 2 | $31 |
| Tempus AI, Inc | 1 | $28 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$645,928 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 22 | $19,472 |
| QuviviqDaridorexant Hcl | 11 | $6,930 |
| Lurasidone Hcl | 34 | $6,652 |
| Aripiprazole | 92 | $2,834 |
| Buspirone Hcl | 135 | $2,802 |
| Duloxetine Hcl | 181 | $2,529 |
| Bupropion XlBupropion Hcl | 91 | $2,114 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $1,802 |
| Doxepin Hcl | 46 | $1,713 |
| Sertraline Hcl | 87 | $1,680 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 39 | $1,647 |
| Clozapine | 13 | $1,647 |
| Olanzapine | 72 | $1,518 |
| Quetiapine Fumarate | 145 | $1,508 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $1,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $796 | $19,47222 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $24,382 | $6,93011 claims |
| Almatica Pharma LLCSertraline Hcl | $65 | $1,68087 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Blue Bell
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.